We described two cases of retinopathy due to antimalarial drugs and evaluated drug screening methods in antimalarial treatment. We reviewed our clinical records, fundus photographs, visual fields and the fluorescein angiographies of two patients from our retina referral department. The first case arose due to the misinterpretation of test results, despite the presence of adequate screening tests. The second case arose because of the inadequate information about the importance of screening tests.
INTRODUCTION
The diagnosis of advanced chloroquine and hydroxychloroquine retinopathy is based on the combined presence of parafoveal pigment epithelial atrophy as seen on fundus biomicroscopy, and acquired paracentral scotoma on threshold visual field testing using the 10-2 program with white test light on a Humphrey perimeter Here we present two cases of antimalarial retinal toxicity which resulted with severe visual impairment. Old and new screening methods to rule out possible ocular toxicity, the dose monitoring guidelines and the follow up strategy are subsequently discussed.
Both cases were screened for color vision defects with 25 plates of Ischiara test. The vision field tests were performed with The Humphrey Visual Field Analyzer (HFA; Carl Zeiss Meditec, Dublin, CA) in our department. All previous vision field tests were also performed with The Humphrey Visual Field Analyzer. For each patient, fundus flourescein angiography and fundus photography were performed to diagnose maculopathy.
CASE REPORT Case 1.
A 24-year old woman (52 kg and 155cm tall) with a 6-year history of SLE was seen for retinal consultation on February 14, 2006 in our clinic. She had been taking a daily dose of 500 mg of chloroquine (9.62 mg/kg/day) for 2 years, 250 mg of chloroquine (4.81 mg/kg/day) for 1 year, 250 mg of chloroquine (4.81 mg/kg/day) once in two days for 2 years, 250 mg of hydroxychloroquine (3.84 mg/kg/day) for 2 months.
Best corrected visual acuity (BCVA) was 7/10 bilaterally, color vision was compromised. 
DISCUSSION
Chloroquine and Hydroxychloroquine are widely used drugs in the treatment of rheumatoid diseases, and they might cause serious retinal toxicity, when used in high doses and taken for a long period of time. The most recently published guidelines by the American Academy of Ophtalmology (AAO) committee describe two patient groups: low and high risk patients. The level of risk for patients receiving antimalarials is determined by patient-related factors and the amount and duration of drug usage (Table I) 1 . Patients should have a complete baseline ophthalmic examination within the first year of treatment and not necesseraly before starting treatment. The first investigation must include retinal examination through a dilated pupil and testing of central visual field sensitivity by Amsler grid or Humphrey 10-2 testing 1 . If the patient is in a low risk category and the examination results are normal, no further ophthalmologic testing is needed for the next 5 years. For patients in a high risk category annual eye examinations are recommended. Studies performed on patients using Chloroquine and Hydroxychloroquine revealed that the daily doses are more important than the cumulative dose [2] [3] [4] . It should be explained to patients that toxicity is unlikely but not impossible in the first five years of usage. Although the AAO suggest that color vision testing be optional, Easterbrook published that it is a very useful test to detect early maculopathy 3 .
Easterbrook also recommended Humphrey 10-2 visual field testing, only if the best visual acuity is not 6/6, color vision is disturbed or if the patient is symptomatic 3 . 
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There is no consensus in different parts of the world about the screening frequency for "high risk" or "low risk" patients, and there is no standard test for screening to detect early maculopathy [1] [2] [3] [4] [5] [6] [7] [8] [9] . But there is a world wide acceptance in the description of low or high risk patients and we also use the same terminology in our clinic. The Royal College of Ophtalmologists guidelines recommend a baseline ophthalmic examination including best corrected visual acuity, fundoscopy, and a central visual field test 8 . Patients should be warned to report any visual disturbance and may be given an Amsler chart to use monthly. No further ophthalmic examination is needed unless the patient is symptomatic 8 .
The most frequently used follow up tests are Amsler grid and 10/2 visual field testing which concern examination of the macula. However, some centers use 40/2 visual field testing for follow up, as was the situation in Case 1. There are also some new tests mentioned in the literature, pointing to early detection of maculopathy, such as multifocal ERG (mfERG), high speed ultra high resolution optical coherence tomography (hsUHR-OCT) and blue-yellow perimetry. The sensitivity and specifity of these tests are not yet known and the availability and interpretation of these test results are a great concern [9] [10] [11] .
The two cases of advanced maculopathy mentioned here were diagnosed during a 5 year period (5 years and 3 months in Case 1; 3 years and 4 months in Case 2). These cases are both established maculopathy cases, where toxicity possibly started months before the diagnosis. In Case 1, the test results were misinterpreted by the patient's rheumatologist and she should have been referred to an ophthalmologist. In Case 2, the patient was poorly informed about the importance of follow up procedures. The information procedure should be done more seriosly.
We are now preparing a more detailed "patients' informed consent form" in our clinic and we are going to publish the results of our clinical protocol which was prepared in accordance with the screening methods mentioned in studies from our country 12, 13 .
Although the mentioned doses are monitored and most patients are under control, there are still some patients suffering from retinopathy. Since 2002, 16 more cases have been reported in the literature, suffering from antimalarial retinopathy. We now add two more cases to these 14 .
Advanced cases of maculopathy have been considered rare, but still continue to be diagnosed in the community. Thus, we still need better screening protocols and we still need to find better ways to inform patients about the first signs of maculopathy to eliminate this irreversibile but preventable dramatic result.
